TherapeuticsMD, Inc. (TXMD) Short Interest Update
TherapeuticsMD, Inc. (NASDAQ:TXMD) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 55,856,043 shares, an increase of 35.8% from the October 13th total of 41,131,584 shares. Based on an average daily volume of 2,240,090 shares, the short-interest ratio is presently 24.9 days. Currently, 32.1% of the company’s shares are sold short.
A number of research analysts have issued reports on the stock. Cowen and Company restated an “outperform” rating and set a $16.00 target price (up from $13.00) on shares of TherapeuticsMD in a research report on Monday, November 6th. Deutsche Bank AG restated a “buy” rating and set a $10.00 target price on shares of TherapeuticsMD in a research report on Wednesday, September 13th. Cantor Fitzgerald restated an “overweight” rating and set a $33.00 target price on shares of TherapeuticsMD in a research report on Tuesday, August 15th. Jefferies Group LLC reiterated a “buy” rating and issued a $15.00 price target on shares of TherapeuticsMD in a research report on Tuesday, September 26th. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $10.00 price target on shares of TherapeuticsMD in a research report on Thursday, August 31st. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. TherapeuticsMD has an average rating of “Buy” and a consensus target price of $15.25.
Shares of TherapeuticsMD (TXMD) opened at $5.67 on Friday. TherapeuticsMD has a 52-week low of $3.50 and a 52-week high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. The business had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. TherapeuticsMD’s revenue for the quarter was down 19.7% on a year-over-year basis. During the same period last year, the company posted ($0.13) EPS. equities analysts expect that TherapeuticsMD will post -0.39 earnings per share for the current fiscal year.
In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were bought at an average cost of $5.99 per share, for a total transaction of $29,950.00. Following the transaction, the director now owns 3,555 shares in the company, valued at approximately $21,294.45. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 23.92% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Managed Account Services Inc. increased its stake in TherapeuticsMD by 5.5% during the 2nd quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock worth $101,000 after purchasing an additional 1,000 shares in the last quarter. Amalgamated Bank increased its stake in TherapeuticsMD by 7.2% during the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after purchasing an additional 1,322 shares in the last quarter. Principal Financial Group Inc. increased its stake in TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after purchasing an additional 818 shares in the last quarter. Traynor Capital Management Inc. increased its stake in TherapeuticsMD by 14.0% during the 2nd quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock worth $123,000 after purchasing an additional 2,799 shares in the last quarter. Finally, Virtu KCG Holdings LLC bought a new stake in TherapeuticsMD during the 2nd quarter worth approximately $157,000. 71.40% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/therapeuticsmd-inc-txmd-short-interest-update/1694568.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.